# OnCo record nct06767813 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06767813/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06767813", "NCT06767813" ;
  schema:name "Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms"@en ;
  schema:description "A phase 2 trial of Gemcitabine and Anlotinib in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06767813/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06767813> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-03-19" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/anlotinib/>, <https://onco.cc/drugs/tqb2868/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> .